-tide
A peptide: a short chain of amino acids. Many hormone-like drugs carry it, often with a more specific stem in front.
- Drugs ending in -tide: 160
- Approved somewhere: 34
- With a US drug page: 35
Approved and clinical-stage drugs in ChEMBL whose names ending in -tide or one of its sub-stems, matched by spelling; those with a US drug page link to it.
| Acts on | |||
|---|---|---|---|
| Afamelanotide | Approved | MC1R | Melanocortin receptor 1 agonist |
| Bremelanotide | Approved | MC4R | Melanocortin receptor 4 agonist |
| Bulevirtide | Approved | SLC10A1 | Bile acid transporter inhibitor |
| Defibrotide sodium | Approved | PLG | Plasminogen activator |
| Ecallantide | Approved | KLKB1 | Plasma kallikrein inhibitor |
| Enfuvirtide | Approved | ENV | Transmembrane glycoprotein gp41 inhibitor |
| Eptifibatide | Approved | ITGA2B, ITGB3 | Integrin alpha-IIb/beta-3 inhibitor |
| Etelcalcetide | Approved | CASR | Calcium sensing receptor agonist |
| Linaclotide | Approved | GUCY2C | Heat-stable enterotoxin receptor agonist |
| Motixafortide acetate | Approved | — | — |
| Plecanatide | Approved | GUCY2C | Heat-stable enterotoxin receptor agonist |
| Pramlintide | Approved | CALCR, RAMP1, CALCR, RAMP3, CALCR, RAMP2 | Amylin receptor AMY1, CALCR/RAMP1 agonist |
| Setmelanotide | Approved | MC4R | Melanocortin receptor 4 agonist |
| Tirzepatide | Approved | GIPR, GLP1R | Gastric inhibitory polypeptide receptor agonist |
| Ziconotide | Approved | CACNA1B | Voltage-gated N-type calcium channel alpha-1B subunit blocker |
| Ziconotide acetate | Approved | CACNA1B | Voltage-gated N-type calcium channel alpha-1B subunit blocker |
| Defibrotide | Phase 3 | ADORA2A, ADORA2B, PLG, ADORA1, F2 | Adenosine A2 receptor agonist |
| Elamipretide | Phase 3 | — | — |
| Motixafortide | Phase 3 | CXCR4 | C-X-C chemokine receptor type 4 antagonist |
| Peginesatide | Phase 3 | EPOR | Erythropoietin receptor agonist |
| Rusfertide | Phase 3 | — | — |
| Rusfertide acetate | Phase 1 | — | — |
| Setmelanotide hydrochloride | Phase 1 | — | — |
| Gozetotide | Approved | — | Diagnostic agent |
| Mifamurtide acid | Approved | NOD2 | Nucleotide-binding oligomerization domain-containing protein 2 other |
| Vipivotide tetraxetan lutetium | Approved | FOLH1, DNA | Glutamate carboxypeptidase II binding agent |
| Aclerastide | Phase 3 | — | — |
| Albuvirtide | Phase 3 | ENV, HIV1 | GP41 inhibitor |
| Avexitide | Phase 3 | GLP1R | Glucagon-like peptide 1 receptor antagonist |
| Balixafortide | Phase 3 | CXCR4 | C-X-C chemokine receptor type 4 antagonist |
| Brimapitide, c-terminal acid | Phase 3 | MAPK10 | c-Jun N-terminal kinase 3 inhibitor |
| Cagrilintide | Phase 3 | — | — |
| Cilengitide | Phase 3 | ITGAV, ITGB3, ITGAV, ITGB5 | Integrin alpha-V/beta-3 antagonist |
| Dirucotide | Phase 3 | — | — |
| Enlicitide | Phase 3 | — | — |
| Fexapotide | Phase 3 | — | — |
| Larazotide | Phase 3 | CHRNA3, CHRNB4 | Neuronal acetylcholine receptor; alpha3/beta4 partial agonist |
| Retatrutide | Phase 3 | GCGR, GLP1R, GIPR | Glucagon receptor agonist |
| Sovatelitide | Phase 3 | — | — |
| Alizulatide vixocianine | Phase 2 | — | — |
| Anfibatide | Phase 2 | GP1BA | Platelet glycoprotein Ib alpha chain antagonist |
| Certepetide | Phase 2 | — | — |
| Danegaptide | Phase 2 | — | — |
| Davalintide | Phase 2 | CALCRL, CALCR, RAMP1 | Calcitonin gene-related peptide type 1 receptor agonist |
| Dazdotuftide | Phase 2 | — | — |
| Dolcanatide | Phase 2 | GUCY2C | Heat-stable enterotoxin receptor agonist |
| Dusquetide | Phase 2 | — | — |
| Edratide | Phase 2 | — | — |
| Etarfolatide | Phase 2 | — | — |
| Hepalatide | Phase 2 | SLC10A1 | Bile acid transporter inhibitor |
| Lancovutide | Phase 2 | — | — |
| Livoletide | Phase 2 | — | — |
| Lucicebtide | Phase 2 | — | — |
| Mibenratide | Phase 2 | — | Unknown |
| Modimelanotide | Phase 2 | MC3R, MC1R | Melanocortin receptor 3 agonist |
| Nangibotide | Phase 2 | TREM1 | Triggering receptor expressed on myeloid cells 1 inhibitor |
| Olatorepatide | Phase 2 | — | — |
| Paluratide | Phase 2 | — | — |
| Pegmispotide | Phase 2 | — | — |
| Peptide t | Phase 2 | — | — |
| Peptide yy human (3-36) | Phase 2 | NPY2R | Neuropeptide Y receptor type 2 agonist |
| Pezadeftide | Phase 2 | — | — |
| Pobrolitide | Phase 2 | — | — |
| Recanaclotide | Phase 2 | — | — |
| Redasemtide | Phase 2 | — | — |
| Rimtoregtide | Phase 2 | — | — |
| Rotigaptide | Phase 2 | — | — |
| Rusalatide | Phase 2 | — | — |
| Solnatide | Phase 2 | — | — |
| Sulglicotide | Phase 2 | — | — |
| Talfirastide | Phase 2 | MAS1 | Proto-oncogene Mas agonist |
| Talogreptide mesaroxetan | Phase 2 | — | — |
| Tozuleristide | Phase 2 | — | Diagnostic |
| Vanutide cridificar | Phase 2 | APP | Amyloid-beta A4 protein vaccine antigen |
| Vipivotide tetraxetan gallium | Phase 2 | — | — |
| Zelenectide pevedotin | Phase 2 | — | — |
| Avexitide acetate | Phase 1 | — | — |
| Brimapitide | Phase 1 | MAPK10 | c-Jun N-terminal kinase 3 inhibitor |
| Colulintide | Phase 1 | — | — |
| Dalazatide | Phase 1 | — | — |
| Eloralintide | Phase 1 | — | — |
| Gersizangitide | Phase 1 | — | — |
| Macupatide | Phase 1 | — | — |
| Nisotirostide | Phase 1 | — | — |
| Noraramtide | Phase 1 | — | — |
| Pegloprastide | Phase 1 | — | — |
| Peptide B27PD | Phase 1 | — | — |
| Petrelintide | Phase 1 | — | — |
| Rugecitide | Phase 1 | — | — |
| Ruxotemitide | Phase 1 | — | — |
| Tifuvirtide | Phase 1 | — | — |
| Tigapotide | Phase 1 | — | — |
| Vipivotide tetraxetan | Phase 1 | — | — |
| Xelafaslatide | Phase 1 | — | — |
| Zelenectide | Phase 1 | — | — |
| Zendusortide | Phase 1 | — | — |
| Ceruletide | — | CCKAR | Cholecystokinin A receptor agonist |
| Mazdutide | Phase 3 | — | — |
| Cotadutide | Phase 2 | GCGR, GLP1R | Glucagon receptor agonist |
| Efinopegdutide | Phase 2 | GLP1R, GCGR | Glucagon-like peptide 1 receptor agonist |
| Pegapamodutide | Phase 2 | GLP1R | Glucagon-like peptide 1 receptor agonist |
| Pemvidutide | Phase 2 | — | — |
| Survodutide | Phase 1 | GLP1R, GCGR | Glucagon-like peptide 1 receptor agonist |
| Exenatide | Approved | GLP1R | Glucagon-like peptide 1 receptor agonist |
| Lixisenatide | Approved | GLP1R | Glucagon-like peptide 1 receptor agonist |
| Efpeglenatide | Phase 3 | GLP1R | Glucagon-like peptide 1 receptor agonist |
| Pegsebrenatide | Phase 2 | GLP1R | Glucagon-like peptide 1 receptor agonist |
| Vurolenatide | Phase 2 | — | — |
| Pegloxenatide | Phase 1 | — | — |
| Albiglutide | Approved | GLP1R | Glucagon-like peptide 1 receptor agonist |
| Dulaglutide | Approved | GLP1R | Glucagon-like peptide 1 receptor agonist |
| Liraglutide | Approved | GLP1R | Glucagon-like peptide 1 receptor agonist |
| Semaglutide | Approved | GLP1R | Glucagon-like peptide 1 receptor agonist |
| Teduglutide | Approved | GLP2R | Glucagon-like peptide 2 receptor agonist |
| Ecnoglutide | Phase 3 | — | — |
| Glepaglutide | Phase 3 | — | — |
| Taspoglutide | Phase 3 | GLP1R | Glucagon-like peptide 1 receptor agonist |
| Elsiglutide | Phase 2 | GLP2R | Glucagon-like peptide 2 receptor agonist |
| Froniglutide | Phase 2 | — | — |
| Beinaglutide | — | — | — |
| Tecemotide | Phase 3 | MUC1 | Mucin-1 vaccine antigen |
| Tertomotide | Phase 3 | — | — |
| Amilomotide | Phase 2 | APP | Amyloid-beta A4 protein vaccine antigen |
| Disomotide | Phase 2 | — | — |
| Ederimotide | Phase 2 | — | — |
| Enavermotide | Phase 2 | — | — |
| Etimumotide | Phase 2 | — | — |
| Imsamotide | Phase 2 | — | — |
| Marlumotide | Phase 2 | — | — |
| Omramotide | Phase 2 | — | — |
| Ovemotide | Phase 2 | — | — |
| Oximbomotide | Phase 2 | — | — |
| Quazomotide | Phase 2 | — | — |
| Sucantomotide | Phase 2 | — | — |
| Tiplimotide | Phase 2 | — | — |
| Vorumotide | Phase 2 | — | — |
| Baloramotide | Phase 1 | — | — |
| Elpamotide | Phase 1 | — | — |
| Trofinetide | Approved | — | Unknown |
| Nerinetide | Phase 3 | — | — |
| Davunetide | Phase 2 | Tubulin | Tubulin stabiliser |
| Cibinetide | Phase 1 | CSF2RB, EPOR | Innate repair receptor agonist |
| Abaloparatide | Approved | PTH1R | Parathyroid hormone receptor agonist |
| Palopegteriparatide | Approved | PTH1R | Parathyroid hormone receptor agonist |
| Teriparatide | Approved | PTH1R | Parathyroid hormone receptor agonist |
| Teriparatide acetate | Phase 3 | PTH1R | Parathyroid hormone receptor agonist |
| Eneboparatide | Phase 1 | — | — |
| Zelpultide alfa | Phase 1 | — | — |
| Lanreotide | Approved | SSTR5, SSTR2 | Somatostatin receptor 5 agonist |
| Octreotide | Approved | Somatostatin receptor | Somatostatin receptor agonist |
| Depreotide trifluoroacetate | Approved | — | Diagnostic agent |
| Pasireotide | Approved | SSTR5, SSTR2, SSTR1, SSTR3 | Somatostatin receptor 5 agonist |
| Edotreotide | Phase 3 | — | — |
| Vapreotide | Phase 3 | SSTR2, SSTR3, SSTR5 | Somatostatin receptor 2 agonist |
| Pentetreotide | Phase 2 | — | — |
| Ucasareotide dasaroxetan | Phase 2 | — | — |
| Veldoreotide | Phase 2 | SSTR2, SSTR4, SSTR5 | Somatostatin receptor 2 agonist |
| Nendratareotide uzatansine | Phase 1 | — | — |
| Satoreotide tetraxetan | Phase 1 | — | — |
| Satoreotide trizoxetan | Early phase 1 | — | — |
Stem from WHO, The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances (2024); description written by Arca. Drugs, stages, targets and mechanisms from ChEMBL (CC BY-SA 3.0). WHO